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The subchronic (90-day) toxicity of esteriﬁed propoxylated glycerol (EPG) was assessed in micropigs. Ani-
mals (5/sex/group) received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the
study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively. Corn oil served as the vehicle control
(0 g/kg bw/day). Subsets of animals were evaluated at Week 6; the remainder between Weeks 12 and
14. With the exception of liver and serum vitamin levels, statistically signiﬁcant difference between con-
trol and EPG groups were seen sporadically, and with no apparent connection to treatment and/or no
consistency across time intervals. EPG intakes of 3 and 5 g/kg bw/day, but not at 1.5 g/kg bw/day were
associated with signiﬁcantly lower serum 25-OH vitamin D levels. Serum total vitamin D levels were
signiﬁcantly lower across all EPG groups. There were also trends toward lower levels of liver vitamins
A and E among EPG-treated animals, but the effects were less consistent. The effects on vitamin levels
observed in EPG-treated animals were not accompanied by any signs of vitamin deﬁciency (e.g., effects
on growth, clinical signs, or clinical pathology), and might have been related to the larger mass of EPG
acting as a lipid ‘‘sink’’ during transit in the gastrointestinal tract.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction
Esteriﬁed propoxylated glycerols (EPGs) represent a family of
fat- and oil-like substances, resembling triglycerides in structure
and appearance, but modiﬁed to prevent or limit their digestion
when consumed in food. They consist of multiple propylene glycol
units inserted between the glycerol and fatty acid moieties of fats
and oils. Their poor absorption results in a low- to no-calorie
proﬁle when substituted for fat in the diet.
The present study examined safety of a hydrogenated version of
EPG that is considered the ‘‘core’’ version (H-EPG-05-HR/SO 9:1)2
in micropigs (Sus scrofa) following administration in the feed forup to 90 days (13 weeks). The micropig is considered an appropriate
model species because like humans, they are true omnivores and
share many important features of anatomy, physiology, and function
of the gastrointestinal systems (Bode et al., 2010).2. Materials and methods
This study was sponsored by ARCO Chemical Company, Newton
Square, Pennsylvania and Best Foods, Somerset, New Jersey. It was
conducted at T.P.S., Inc., Mt. Vernon, Indiana, from February to
May, 1993 (in-life portion), in compliance with the principles of
Good Laboratory Practice (GLP) regulations of the United States
Food and Drug Administration (FDA).2.1. Animals
Young healthy male and female Yucatan Micropigs were
obtained from Charles River Laboratories, Windham, ME. Twenty
male micropigs weighing 12.808–18.189 kg and twenty female
micropigs weighing 10.991–19.384 were started on the study
following an acclimation period of approximately 5.5 months.
Following the acclimation period, animals (8–10 months old; 5/
sex/group) of adequate body weight and in good health
Table 1
EPG concentration and group composition.
Group Treatment Number of
animals/sexb
EPG*
g/kg/day
Dietary concentration+
% (w/w)
Control (AVI1)** 0 0 5
Low EPG (AVI2) 1.5 5 5
Mid EPG (AVI3) 3 10 5
High EPG (AVI4) 5 17 5
* Approximate levels; animals received feed containing 5%, 10%, and 17% EPG,
mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG,
respectively.
** The basic diet was supplemented with 4% (w/w) corn oil; test diets contained
EPG and 4% (w/w) corn oil as vehicle.
+ % (w/w) = weight of EPG per weight of basal diet including corn oil.
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including slit lamp biomicroscopy, urinalysis, and clinical pathol-
ogy) were stratiﬁed by weight and assigned to each of the study
groups (Table 1) based on a computer-generated randomization
schedule.
2.2. Test article and dosing
The test material, esteriﬁed propoxylated glycerol [H-EPG-05
HR/SO 9:1; EPG (stabilized with tocopherols, including a-tocoph-
erol), Lot Nos. 753485 and 850201], an off-white solid, was
provided by the sponsor. Bulk (55-gallon drum containers) mate-
rial was stored at 20 C until thawed, repackaged (5-gallon),
and stored at 25 to 3 C. Prior to use, working aliquots were
thawed and stored refrigerated (0–11 C).
Animals received feed containing up to 5%, 10%, and 17% EPG,
mixed accordingly throughout the study to deliver 1.5, 3, and
5 g/kg bw/day of EPG, respectively. The vehicle, corn oil, served
as a control (0 g/kg bw/day).
The carrier was Certiﬁed Agway Prolab Minipig Diet Meal
(Lots No. Jul 16 92 W2 and Dec 9 92 W1); corn oil (Mazola
100% pure corn oil, Lot No. 2321) was added at 4% (w/w). The fat
content in of the diets (with corn oil) was approximately 7% by
weight; the remaining major components of the feed were approx-
imately 17% protein, 13% crude ﬁber, 10% moisture, and 7% ash.
For each diet, the appropriate amount of EPG (corn oil only for
control) was placed in a glass beaker with corn oil; the mixture was
stored at 55 C for at least 1 h, followed by stirring on a magnetic
stir plate until dissolved. The EPG/corn oil blend and a fraction of
the total feed was placed in a mixer (Univex M-20 or Hobart
V-1401 mixer) for approximately 5 min; any residue remaining
on the beaker and stir bar was rinsed into the mix with approxi-
mately 100 g of additional corn oil, followed by feed that was set
aside. This mixture was blended in a ribbon mixer with the
remaining feed for approximately 10 min.
Each diet was prepared the day before study initiation and
weekly thereafter. Prepared diets were stored protected from light
in plastic containers lined with food-grade plastic bags at 32–52 C.
Analysis of the (weekly) feed for EPG revealed the following range
of concentrations for each of the 5%, 10%, and 17% diets, respec-
tively: 4.5–5.1%; 8.4–9.9%; and 13.3–15%.
Animals were fed three times per day (morning, noon, and
evening) for at least 90 days (13 weeks), with approximately three
hours between feedings. The EPG portion of the diet was divided,
weighed, and provided in the morning and evening feedings. Any
supplemental feed (control feed) that might be needed to provide
enough calories3 was administered during the noon feeding. EPG-
containing feed was weighed before and after the feeding period,
unless none remained (i.e., marked as ‘‘consumed’’).
2.3. Housing
Animals were housed individually in adjacent runs (approxi-
mately 30  60) with chain-link wire sides, epoxy coated ﬂoors,
and hardwood chip bedding, in an isolated temperature – (54–81
F) and humidity – (20–86%) controlled animal room with ﬁltered
air supply (10–15 changes/h) and cycled lighting (12-h light/12-h
dark). Minimum and maximum room temperatures and humidity
were recorded daily. The runs were cleaned daily and sanitized
approximately every 2 weeks. Fresh tap water was available ad libi-3 Additional amounts of the control diet (containing 4% corn oil) were administered
across all groups, based on an algorithm, to ensure each animal received approxi-
mately 500 to 600 g of feed per day. The levels ranged from 280 g/day in an animal
weighing 9 kg to 15 g/day in a 19.5-kg pig; no supplementation would have been
required once body weight reached 20 kg.tum from automatic water nipples. Concentrations of contami-
nants in the feed and drinking water were considered to be
below levels capable of compromising the study.
2.4. Observations
2.4.1. Mortality and clinical signs
All animals were observed twice daily throughout the test
period for mortality, moribundity, general health, physical appear-
ance, and pharmacological, toxicological, or behavioral effects. This
included visual inspection of the feces for appearance, consistency
and any evidence of phase separation (i.e., appearance of oily layers
or deposits in the stools).
2.4.2. Body weight and weight gain
Individual body weights were obtained on a single beam bal-
ance (Nordic Forge 4600) during pre-test, day-1, and weekly there-
after. Body weights used for calculating the relative organ weights
at necropsy were obtained after an overnight fast immediately
prior to necropsy.
2.4.3. Feed consumption and EPG intake
Food consumption was recorded daily during the study. Feed
efﬁciency [weight gain (g)/feed consumed (g)] was calculated on
a weekly basis.
2.4.4. Physical and ophthalmic examination
Each animal was subjected to a detailed physical examination
by the attending veterinarian at pre-test and during Weeks 6 and
13; a general physical examination was conducted weekly other-
wise by a technician. Animals were tested for the presence of fecal
parasites at pre-test and during Weeks 7 and 14.
Ophthalmic examinations (including slit-lamp biomicroscopy)
were performed by a Board-certiﬁed veterinary ophthalmologist
prior to study initiation and during Weeks 6 and 13. Prior to exam-
ination, animals were sedated with 20–25 mg/kg of Ketamine HCl
(Ketaset, Aveco, Fort Dodge, IA, Lot Nos. 440164 and 440176,) via
intramuscular (i.m.) injection. The eyes were dilated with Tropica-
mide Ophthalmic Solution, USP 1% (Schein, Port Washington, NY,
Lot Nos. 91K410 and 92J800).
2.4.5. Hematology, clinical chemistry, and urinalysis
Blood samples for hematology and serum chemistry were col-
lected from the anterior vena cava after an overnight fast. Collec-
tions were made at pre-test and during Weeks 6 and 13. RBC
count, hematocrit, MCV, MCH, MCHC, WBC count, hemoglobin,
and platelet count were measured using a Cell-Dyn 900 Hematol-
ogy (Sequoia-Turner). ProT and APTT were measured using a BBL
Fibrometer. Accustain™ (Sigma) was used on bone marrow smears
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the new methylene blue stain. Clinical chemistry parameters were
measured by the Beckman Synchron CX5 System (Beckman Instru-
ments, Inc., Brea, California.)
A 24-h urine sample was collected in stainless steel metabolism
cages from all animals (hydrated with tap water at 20 mL/kg) pre-
test and during Week 6, and Week 12 or 13. Urinalysis and urine
chemistry were performed using Chemstrip 8 (Boehringer-Mann-
heim Diagnostics, Inc.) and Beckman Synchron CX5 System
(Beckman Instruments, Inc., Brea, California.), respectively.
2.4.6. Liver and serum vitamins
At scheduled necropsy, a separate aliquot of blood was drawn
before pentobarbital administration. The clotted sample was
centrifuged and the serum stored at 20 C until analysis for
25-hydroxyvitamin D and total vitamin D. Analyses for 25-hydrox-
yvitamin D and total vitamin D were performed by radioimmuno-
assay detailed in Hollis et al. (1993) and HPLC according to the
procedure described in Liel et al. (1988) with minor modiﬁcations,
respectively.
For liver vitamins A and E (control and 5 g/kg bw/day animals
only), a representative sample of liver from each lobe was har-
vested at necropsy, weighed, frozen in liquid nitrogen, and stored
at 70 C until analyzed. Duplicate samples were taken from adja-
cent sites. Analyses for liver vitamins A and E were performed by
HPLC and gas chromatography (GC) using ﬂame ionization detector
(FID), respectively.
2.4.7. Tissue EPG
At scheduled necropsy, duplicate representative samples of the
liver (each lobe), kidneys, spleen, and adipose tissue were har-
vested from each animal, weighed, and stored at approximately
20 C until analyzed. EPG was determined in samples from all
control and 5 g/kg bw/day EPG animals. Tissue samples were ana-
lyzed using Waters 845 HPLC and data system with a reverse
phase, Beckman Ultrasphere ODS (25 cm  4.6 mm ID), Dupont
Zorbax Rx-C8 guard cartridge.
2.4.8. Fecal analysis
During Week 6 and Weeks 12 or 13, animals (5/sex) from the
control and 5 g/kg bw/day EPG groups were housed in stainless
steel metabolism cages in order to collect 24-h fecal samples.
The samples were weighed, divided in half, and stored at
20 ± 10 C. One set of samples was used for cholesterol, total free
fatty acids, and bile acids analysis. The other half was sent to RTI
(Research Triangle Park, NC) for EPG (triester) and EPG metabolites
(mono- and diester) analysis.
Feces were analyzed for fatty acids, cholesterol, calcium, fat
(ether extract), and total bile acids. Fatty acids and cholesterol
were measured using gas chromatography. The concentration of
calcium in the feces was calculated by comparing the absorbance
of atomized calcium to a standard reference curve, following the
digestion of the feces by a 600 C ash procedure. Fat is extracted
by ethyl ether on a Tecator Soxtec (a fat extraction apparatus),
ethyl ether is evaporated, and then the residual fat is weighed.
Concentration of bile acids is quantiﬁed by measuring the genera-
tion of NADH (spectrophotometrically or spectroﬂuorimetrically)
from NAD+ during the oxidation of 3-a-hyroxysteroids.
2.4.9. Bowel transit times
Bowel transit time was determined for each animal from the
control and 5 g/kg bw/day EPG groups during pre-test, Week 6,
and Weeks 12 or 13. Wood chips were removed from the runs
3–4 days before this procedure. Radio-opaque markers (Epidural
Catheter, Cat. No. 4912-18, Concord Portex, Keene, NH, Lot Nos.
205124 and 212220) were cut into 20 sections (2-mm each)and subsequently placed in a No. 13 Torpac gelatin capsule (Tor-
pac, Ltd., Toronto, Canada). Prior to placement into metabolism
cages, each animal received a capsule orally after feeding. During
pre-test, feces were collected at approximately 0–4, 4–8, 8–12,
and 12–24 h post-dosing. During Week 6, feces were collected at
0–24, 24–30, 30–26, and 26–48 h post-dosing. During Week 12
or 13 feces were collected separately at 0–24, 24–48, 48–60, and
60–72 h post-dosing. Each sample was packaged in a labeled plas-
tic bag and frozen until X-rayed to determine the number of mark-
ers per fecal sample.2.4.10. Necropsy, organ weights, and histopathological examination
Following at least 13 weeks of treatment and an overnight fast,
animals were sacriﬁced in the order designated by a computer-
generated randomization schedule. All animals were anesthetized
with sodium pentobarbital, weighed, exsanguinated, and necrop-
sied. The necropsy included gross examination of: the external sur-
faces of the body; thoracic, abdominal, and pelvic, cavities and
enclosed organs; and the head and cervical organs and tissues.
The adrenals, brain, heart, pituitary, kidneys, liver, spleen,
cecum, thyroid, prostate and gonads (testes and ovaries) were
removed and weighed (paired organs separately).
All lesions identiﬁed during gross examination were examined
microscopically, along with the following major organs and
tissues: adrenals; aorta; bone with marrow (costochondral junc-
tion/rib); brain; cecum; cervix; colon; duodenum; epididymides;
esophagus; eyes (both); gallbladder; heart; ileum; jejunum; kid-
neys; liver (all lobes); lung (with mainstem bronchi); mammary
gland (females only); mandibular lymph node; mesenteric lymph
node; ovaries; pancreas; peripheral nerve (with skeletal muscle);
pituitary; prostate; rectum; salivary gland; seminal vesicles; skin;
spinal cord (cervical, mid-thoracic, lumbar); spleen; stomach
(cardiac, fundic, and pyloric regions); testes; thymus; thyroid (with
parathyroid if in thyroid section); tongue; trachea; urinary
bladder; uterus; and vagina. Tissues were preserved in 10% neutral
buffered formalin (or other suitable ﬁxative), processed, embed-
ded, sectioned, stained with hematoxylin and eosin, and examined
by a qualiﬁed pathologist.2.4.11. Statistical analyses
Statistical methods used in the evaluation of numerical data
were those of Dunnett, an analysis of variance (ANOVA) model to
compare one or more treatment groups to a control group
(Dunnett, 1955, 1964). Statistical signiﬁcance was assessed
through p values equal to or less than 0.05 or 0.01.3. Results
3.1. Mortality and clinical signs
All micropigs survived to the end of the study.
There was evidence of pneumonia across all groups upon nec-
ropsy and histopathological examination (see below), but no signs
otherwise. Clinical signs seen in animals receiving EPG were
limited to: ‘‘distended abdomen’’ in one male receiving 1.5 g/kg
bw/day, ﬁrst seen at Week 1 and last seen at Week 14; ‘‘appears
thin’’ in one female from each the 1.5 g/kg bw/day (ﬁrst seen at
Week 1, last seen at Week 14) and 3 g/kg bw/day (ﬁrst seen at
Week 6, last seen at Week 8) groups; and ‘‘lameness–right front
leg’’ seen ﬁrst at Week 12 and last at Week 14 in one 5 g/kg bw/
day female. These isolated observations are not regarded as effects
of EPG treatment.
Visual inspection of the feces showed no phase separation
(i.e., appearance of oily layers or deposits in the stools).
Table 2
Summary of body weights (kg).
Week Male Female
EPG in dieta
(g/kg bw/day)
EPG in dieta
(g/kg bw/day)
0 1.5 3 5 0 1.5 3 5
0 15.5 ± 1.77 15.5 ± 1.80 15.5 ± 1.66 15.2 ± 1.67 14.4 ± 1.93 14.6 ± 2.80 14.8 ± 2.22 15.1 ± 2.88
1 17.1 ± 2.02 17.6 ± 1.89 17.7 ± 1.39 17.5 ± 1.75 15.9 ± 2.24 15.8 ± 3.13 16.6 ± 2.47 16.8 ± 3.18
2 17.5 ± 2.04 17.6 ± 1.84 17.4 ± 1.55 17.5 ± 1.78 16.8 ± 2.12 15.7 ± 3.00 17.2 ± 2.77 17.2 ± 3.00
3 17.2 ± 1.84 17.6 ± 1.57 16.9 ± 1.63 17.5 ± 1.57 16.8 ± 1.72 15.6 ± 3.23 16.7 ± 2.66 17.0 ± 3.16
4 18.7 ± 2.09 18.5 ± 1.42 18.2 ± 1.88 19.0 ± 1.82 18.0 ± 2.05 16.4 ± 3.47 17.6 ± 3.30 18.5 ± 3.02
5 19.5 ± 2.39 19.5 ± 1.77 18.6 ± 1.80 19.9 ± 1.73 19.1 ± 2.02 17.0 ± 3.66 18.5 ± 3.45 18.7 ± 3.63
6 18.7 ± 2.28 19.3 ± 1.87 18.3 ± 1.95 19.3 ± 1.65 17.5 ± 2.20 15.3 ± 3.68 17.5 ± 3.62 17.8 ± 4.00
7 20.3 ± 2.93 20.3 ± 1.89 19.5 ± 1.62 20.6 ± 1.72 19.8 ± 2.15 17.4 ± 3.61 19.5 ± 3.82 19.9 ± 4.02
8 20.6 ± 2.87 20.9 ± 1.77 20.3 ± 1.72 21.4 ± 1.92 20.9 ± 2.30 18.0 ± 4.03 20.6 ± 4.04 20.5 ± 4.14
9 21.4 ± 3.33 21.5 ± 2.04 20.8 ± 1.85 21.7 ± 2.59 21.6 ± 2.62 18.0 ± 4.02 21.0 ± 4.70 20.9 ± 3.97
10 21.9 ± 3.29 22.4 ± 2.12 21.0 ± 2.12 22.6 ± 2.53 22.0 ± 2.48 18.3 ± 4.33 21.9 ± 4.44 21.8 ± 4.50
11 23.2 ± 4.15 23.2 ± 2.34 21.6 ± 2.13 23.4 ± 2.77 22.9 ± 2.48 18.6 ± 4.62 22.5 ± 5.02 22.0 ± 4.18
12 23.1 ± 4.42 23.7 ± 2.14 22.1 ± 2.44 23.6 ± 2.99 23.7 ± 2.71 19.2 ± 4.88 23.3 ± 5.62 22.7 ± 4.60
13 24.0 ± 4.34 24.0 ± 2.67 22.3 ± 2.59 24.1 ± 3.45 23.3 ± 2.97 18.8 ± 4.96 23.2 ± 5.92 22.2 ± 5.36
Values represent mean ± SD, unless otherwise speciﬁed.
Number of animals (N) = 5/group.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
Table 3
Summary of feed consumption (g/day).
Week Male Female
EPG in dieta
(g/kg bw/day)
EPG in dieta
(g/kg bw/day)
0 1.5 3 5 0 1.5 3 5
1 602.1 ± 1.2 601.3 ± 0.4 602.3 ± 1.0 599.6 ± 7.2 597.3 ± 8.6 594.0 ± 12.9 593.9 ± 16.0 598.7 ± 7.3
2 604.5 ± 6.5 603.7 ± 5.8 597.7 ± 0.7 598.9 ± 0.8 601.2 ± 1.9 595.9 ± 9.2 598.0 ± 1.3 604.6 ± 12.8
3 607.6 ± 13.3 604.4 ± 6.8 602.4 ± 0.8 601.2 ± 0.7 601.6 ± 0.9 597.1 ± 9.9 605.5 ± 6.3 608.8 ± 16.4
4 605.0 ± 6.1 604.5 ± 6.6 601.6 ± 2.0 604.7 ± 0.5 601.6 ± 0.7 595.7 ± 12.8 597.5 ± 8.7 615.9 ± 27.1
5 616.5 ± 33.7 608.7 ± 13.3 605.4 ± 6.8 612.6 ± 15.9 607.8 ± 13.0 600.0 ± 14.4 614.3 ± 19.5 621.1 ± 46.5
6 615.3 ± 52.3 615.0 ± 33.1 605.0 ± 12.6 620.5 ± 28.9 610.7 ± 38.1 608.6 ± 29.4 622.3 ± 38.2 629.6 ± 58.6
7 616.2 ± 32.8 615.6 ± 33.4 607.1 ± 12.5 618.5 ± 24.5 607.5 ± 13.1 593.1 ± 17.9 609.9 ± 28.8 624.2 ± 53.2
8 637.8 ± 72.1 625.8 ± 45.5 615.3 ± 26.4 636.4 ± 39.2 626.0 ± 45.5 611.3 ± 28.7 642.6 ± 52.2 651.0 ± 78.1
9 643.4 ± 69.3 638.4 ± 48.8 631.1 ± 43.9 661.1 ± 57.2 646.3 ± 63.7 616.5 ± 43.1 667.3 ± 80.6 667.2 ± 93.2
10 659.2 ± 87.4 656.5 ± 59.3 634.0 ± 47.8 657.2 ± 78.1 647.3 ± 64.6 616.3 ± 43.7 671.9 ± 90.7 660.4 ± 97.3
11 670.1 ± 90.3 681.8 ± 59.4 642.7 ± 54.3 686.7 ± 71.1 667.0 ± 76.0 618.2 ± 49.9 690.3 ± 99.0 680.6 ± 113.5
12 705.9 ± 115.9 705.5 ± 74.8 662.1 ± 65.5 713.1 ± 85.1 694.0 ± 74.0 624.5 ± 62.6 712.8 ± 112.7 683.2 ± 114.5
13 706.8 ± 115.0 722.1 ± 64.3 671.2 ± 69.5 723.8 ± 91.5 721.6 ± 83.9 637.3 ± 67.2 734.2 ± 128.9 699.0 ± 125.6
Values represent mean ± SD, unless otherwise speciﬁed.
Number of animals (N) = 5/group.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
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As Table 2 illustrates, there were no differences among groups in
body weights. However, body weight change among females
receiving 1.5 g/kg bw/day was signiﬁcantly (p 6 0.01 or p 6 0.05)
lower than control from Weeks 2–14 (data not shown). This might
have been related to pneumonia that became evident upon
necropsy and histopathological examination (see below). Statistical
analysis of the data without two animals (AVI2F01 and AVI2F04)
from this group that had the lowest body weight changes showed
no statistical signiﬁcant differences in body weight change.
As expected, some effects on body weights and body weight
changes were seen when animals were placed in metabolism
cages, possibly related to stress.
3.3. Feed consumption and EPG intake
As shown in Table 3, there were no differences among groups in
feed consumption. Weekly feed efﬁciency was generally positive;
negative numbers were seen sporadically, such as during Week 6
(all male and female groups) and Week 13 (all females), but this
mighthavebeenrelated to thestressofhousing inmetabolismcages.The mean weekly achieved intake of EPG/kg body weight/day
among treatment groups, was1.5, 3.1, and 5.1 g/kg bw/day and
comparable to the target value for each of the 1.5, 3, and 5 g/kg
bw/day groups.
3.4. Physical and ophthalmic examination
Fecal examinations for parasites at pre-test indicated arachnid
ova and strongyle eggs to be present. The micropigs were treated
with 1 mL/34 kg SQ IVOMEC 1% (Merck, #TBC-184). Fecal examin-
ations for parasites during Weeks 7 and 14 were negative. The
weekly general physical exams during the study indicated some
of the animals were thin.
Ophthalmic examination did not reveal any ﬁndings related to
treatment.
3.5. Hematology, clinical chemistry, and urinalysis
The results of the clinical pathology and urinalysis are summa-
rized in Tables 4–9. Isolated differences were observed between
the control and EPG groups, but with no evidence of a relationship
to EPG.
Table 4
Hematology values for males.
EPGa
(g/kg bw/day)
N RBC
(106/mm3)
HGB
(g/dL)
HCT
(%)
MCV
(lm3)
MCH
(pg)
MCHC
(g/dL)
PLT
(103/mm3)
PT
(s)
Week 6
0 5 7.73 ± 0.40 14.4 ± 0.3 42.8 ± 2.8 55.6 ± 5.0 18.6 ± 1.4 33.7 ± 2.2 387 ± 72 12.5 ± 0.3
1.5 5 7.47 ± 0.45 14.1 ± 0.4 42.5 ± 1.8 57.0 ± 2.7 18.9 ± 1.1 33.3 ± 1.4 438 ± 85 13.1 ± 0.3
3 5 7.07 ± 0.43 13.9 ± 0.8 41.7 ± 3.0 59.0 ± 2.2 19.7 ± 0.7 33.4 ± 1.7 452 ± 65 12.9 ± 0.3
5 5 7.39 ± 0.87 14.1 ± 0.7 42.7 ± 2.5 58.4 ± 3.9 19.3 ± 1.4 33.1 ± 1.5 454 ± 61 13.0 ± 0.7
Week 13
0 5 7.75 ± 0.55 15.4 ± 0.5 42.1 ± 1.7 54.6 ± 4.2 19.9 ± 1.5 36.6 ± 0.3 458 ± 59 13.9 ± 0.4
1.5 5 7.19 ± 0.43 14.7 ± 0.7 41.2 ± 2.3 57.4 ± 3.6 20.5 ± 1.1 35.8 ± 0.5* 389 ± 38 13.9 ± 0.3
3 5 7.28 ± 0.56 15.2 ± 0.9 42.2 ± 2.7 58.2 ± 3.4 20.9 ± 0.9 36.0 ± 0.5 417 ± 120 13.5 ± 0.6
5 5 7.36 ± 0.44 15.2 ± 0.6 43.1 ± 2.3 58.6 ± 4.2 20.6 ± 1.4 35.2 ± 0.4** 388 ± 74 13.8 ± 0.3
APTT
(s)
WBC
(103/mm3)
NEUTR
(%)
LYMPH
(%)
MONO
(%)
EOSIN
(%)
BASO
(%)
Week 6
0 5 15.7 ± 0.5 11.7 ± 2.7 60.6 ± 10.1 37.2 ± 11.5 1.0 ± 1.4 1.2 ± 1.3 0
1.5 5 16.4 ± 1.2 14.8 ± 2.0 55.0 ± 11.3 41.0 ± 8.0 1.2 ± 1.1 2.8 ± 3.0 0
3 5 16.2 ± 1.3 17.1 ± 2.0** 58.8 ± 9.7 32.6 ± 5.4 1.6 ± 1.3 7.0 ± 4.9 0
5 5 16.5 ± 1.4 12.0 ± 2.2 53.0 ± 7.5 42.2 ± 6.8 1.0 ± 1.0 3.8 ± 2.9 0
Week 13
0 5 16.9 ± 0.8 13.9 ± 2.3 60.0 ± 7.4 34.6 ± 9.6 4.2 ± 3.5 1.2 ± 1.3 0
1.5 5 16.0 ± 0.6 13.8 ± 1.5 53.0 ± 8.9 43.0 ± 8.0 3.0 ± 1.2 1.0 ± 1.0 0
3 5 16.7 ± 1.3 15.2 ± 2.1 60.2 ± 11.0 36.2 ± 12.4 1.8 ± 2.9 1.8 ± 1.8 0
5 5 16.7 ± 0.7 10.8 ± 0.9* 49.8 ± 2.2 44.2 ± 3.6 3.4 ± 1.9 2.6 ± 1.1 0
Values represent mean ± SD, unless otherwise speciﬁed.
RBC: red blood cell count; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin
concentration; PLT: platelet count; PT: prothrombin time.
APTT: activated partial thromboplastin time; WBC: white blood cell count; NEUTR: neutrophils LYMPH: lymphocyte count; MONO: monocyte count; EOSIN: eosinophil
count; BASO: basophil count.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
* Statistically signiﬁcant at p 6 0.05 by Dunnett’s test.
** Statistically signiﬁcant at p 6 0.01 by Dunnett’s test.
Table 5
Hematology values for females.
EPGa
(g/kg bw/day)
N RBC
(106/mm3)
HGB
(g/dL)
HCT
(%)
MCV
(lm3)
MCH
(pg)
MCHC
(g/dL)
PLT
(103/mm3)
PT
(s)
Week 6
0 5 7.10 ± 0.66 13.3 ± 1.1 41.6 ± 2.3 58.8 ± 3.7 18.8 ± 0.8 32.0 ± 1.5 369 ± 95 12.4 ± 0.4
1.5 5 7.38 ± 0.51 13.7 ± 0.8 41.5 ± 2.7 56.2 ± 4.2 18.6 ± 1.1 33.1 ± 1.1 424 ± 116 12.5 ± 0.3
3 5 7.34 ± 0.46 13.7 ± 0.6 40.9 ± 2.5 55.8 ± 4.0 18.7 ± 1.3 33.6 ± 0.9 453 ± 86 12.5 ± 0.7
5 5 7.23 ± 0.48 13.8 ± 0.3 41.1 ± 2.1 57.0 ± 1.9 19.1 ± 1.0 33.6 ± 1.2 456 ± 131 12.6 ± 0.6
Week 13
0 5 7.10 ± 0.36 14.8 ± 0.2 41.0 ± 1.4 58.0 ± 4.2 20.9 ± 1.4 36.1 ± 1.0 422 ± 106 13.5 ± 0.4
1.5 5 7.48 ± 0.56 15.1 ± 1.0 42.2 ± 4.1 56.4 ± 5.2 20.2 ± 1.3 35.9 ± 1.4 436 ± 111 13.2 ± 1.2
3 5 7.40 ± 0.57 15.0 ± 0.7 42.1 ± 2.1 57.2 ± 5.0 20.3 ± 1.6 35.6 ± 0.4 414 ± 55 13.8 ± 0.4
5 5 7.18 ± 0.51 14.6 ± 0.9 41.2 ± 2.8 57.4 ± 1.1 20.4 ± 0.4 35.6 ± 0.9 355 ± 102 14.1 ± 0.5
APTT
(sec)
WBC
(103/mm3)
NEUTR
(%)
LYMPH
(%)
MONO
(%)
EOSIN
(%)
BASO
(%)
Week 6
0 5 15.9 ± 0.9 12.6 ± 3.8 55.6 ± 11.0 42.6 ± 10.0 0.8 ± 0.8 1.0 ± 1.0 0
1.5 5 16.5 ± 0.4 13.9 ± 2.9 58.4 ± 14.8 39.6 ± 14.2 1.2 ± 0.8 0.8 ± 1.3 0
3 5 15.8 ± 1.0 15.2 ± 3.3 57.8 ± 12.4 38.6 ± 11.2 1.0 ± 0.7 2.6 ± 2.7 0
5 5 15.7 ± 1.2 15.8 ± 7.6 54.0 ± 6.4 39.6 ± 11.7 0.8 ± 0.8 5.6 ± 6.6 0
Week 13
0 5 16.5 ± 1.6 11.1 ± 1.9 44.0 ± 6.4 51.2 ± 6.7 2.6 ± 2.4 2.2 ± 0.8 0
1.5 5 16.2 ± 1.9 12.3 ± 1.5 45.6 ± 17.5 51.6 ± 17.7 1.4 ± 1.5 1.4 ± 1.5 0
3 5 16.2 ± 1.4 13.2 ± 3.2 48.4 ± 12.7 47.0 ± 14.0 1.6 ± 1.8 3.0 ± 1.6 0
5 5 17.6 ± 1.1 11.3 ± 1.5 48.0 ± 8.1 47.8 ± 8.9 2.8 ± 1.5 1.4 ± 0.5 0
Values represent mean ± SD, unless otherwise speciﬁed.
RBC: red blood cell count; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin
concentration; PLT: platelet count; PT: prothrombin time.
APTT: activated partial thromboplastin time; WBC: white blood cell count; NEUTR: neutrophils LYMPH: lymphocyte count; MONO: monocyte count; EOSIN: eosinophil
count; BASO: basophil count.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
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Table 6
Clinical chemistry values for males.
EPGa
(g/kg bw/day)
N AST
(IU/L)
ALT
(IU/L)
GGT
(IU/L)
GLU
(mg/dL)
BUN
(mg/dL)
CREAT
(mg/dL)
CHOL
(mg/dL)
TRIG
(mg/dL)
HDL
(mg/dL)
LDL
(mg/dL)
VLDL
(mg/dL)
Week 6
0 5 41.6 ± 5.1 119.9 ± 13.1 49.4 ± 10.0 76.0 ± 10.1 12.5 ± 3.0 0.86 ± 0.24 83.7 ± 17.4 45.3 ± 18.9 49.3 ± 8.6 25.4 ± 12.4 9.1 ± 3.8
1.5 5 46.8 ± 13.7 104.1 ± 32.2 48.8 ± 5.8 73.1 ± 13.7 14.5 ± 3.1 0.97 ± 0.17 76.8 ± 18.5 59.3 ± 20.5 45.5 ± 12.7 19.5 ± 3.0 11.9 ± 4.1
3 5 39.2 ± 4.6 93.3 ± 14.2 49.7 ± 10.2 74.4 ± 8.7 16.9 ± 2.9 0.90 ± 0.18 87.1 ± 24.2 38.6 ± 16.2 51.8 ± 16.1 27.7 ± 9.9 7.7 ± 3.2
5 5 35.1 ± 10.3 85.4 ± 18.0* 52.0 ± 8.0 76.2 ± 12.3 15.8 ± 2.7 0.98 ± 0.16 79.0 ± 13.8 40.8 ± 15.4 50.1 ± 6.5 20.7 ± 9.2 8.2 ± 3.1
Week 13
0 5 33.8 ± 4.6 78.9 ± 11.2 51.9 ± 14.0 75.1 ± 10.6 16.6 ± 3.2 1.04 ± 0.11 86.0 ± 27.7 30.2 ± 11.0 47.1 ± 13.6 32.9 ± 15.0 6.0 ± 2.2
1.5 5 44.3 ± 14.0 91.0 ± 24.5 52.3 ± 8.5 84.7 ± 13.4 13.3 ± 2.1 1.01 ± 0.12 80.0 ± 10.4 47.2 ± 14.2 47.1 ± 7.2 23.5 ± 6.9 9.4 ± 2.8
3 5 44.7 ± 8.5 101.0 ± 7.6 51.5 ± 7.9 78.6 ± 9.5 15.4 ± 0.7 0.93 ± 0.04 92.1 ± 18.9 42.2 ± 17.9 53.5 ± 9.2 30.2 ± 10.4 8.4 ± 3.6
5 5 35.0 ± 10.3 74.7 ± 2.3 56.5 ± 5.8 70.7 ± 9.8 19.1 ± 1.4 1.02 ± 0.12 90.4 ± 14.7 37.8 ± 13.5 53.3 ± 10.2 29.5 ± 6.9 7.6 ± 2.7
T BILI
(mg/dL)
PHOS
(mg/dL)
T PRO
(g/dL)
ALB
(g/dL)
GLOB
(g/dL)
A/G RATIO CA
(mg/dL)
MG
(mg/dL)
CL
(mEq/L)
NA
(mEq/L)
K
(mEq/L)
Week 6
0 5 0.16 ± 0.02 7.0 ± 0.9 7.0 ± 0.2 3.8 ± 0.3 3.1 ± 0.1 1.2 ± 0.1 11.3 ± 0.4 2.5 ± 0.2 105.3 ± 2.0 141.3 ± 2.1 4.86 ± 0.85
1.5 5 0.16 ± 0.02 7.0 ± 0.2 6.9 ± 0.4 3.3 ± 0.4* 3.5 ± 0.4 1.0 ± 0.2 11.2 ± 0.3 2.4 ± 0.2 103.8 ± 4.3 138.8 ± 2.5 5.07 ± 0.66
3 5 0.14 ± 0.02 7.3 ± 0.4 6.9 ± 0.4 3.5 ± 0.3 3.4 ± 0.3 1.1 ± 0.1 11.1 ± 0.3 2.5 ± 0.2 104.4 ± 3.5 139.9 ± 2.8 4.67 ± 0.57
5 5 0.14 ± 0.02 7.2 ± 0.6 6.9 ± 0.7 3.6 ± 0.2 3.3 ± 0.8 1.1 ± 0.3 11.0 ± 0.4 2.5 ± 0.3 106.2 ± 1.9 141.0 ± 1.4 5.33 ± 0.52
Week 13
0 5 0.14 ± 0.02 7.2 ± 0.4 6.8 ± 0.3 3.8 ± 0.3 3.0 ± 0.2 1.3 ± 0.2 11.2 ± 0.4 2.4 ± 0.1 105.6 ± 2.5 143.6 ± 2.8 4.38 ± 0.48
1.5 5 0.17 ± 0.02 7.3 ± 0.6 6.7 ± 0.2 3.6 ± 0.3 3.1 ± 0.3 1.2 ± 0.2 10.9 ± 0.4 2.4 ± 0.1 107.6 ± 4.8 142.0 ± 2.5 4.92 ± 0.27
3 5 0.15 ± 0.04 6.9 ± 0.5 6.9 ± 0.3 3.7 ± 0.1 3.2 ± 0.3 1.2 ± 0.2 11.0 ± 0.3 2.5 ± 0.2 104.2 ± 3.2 142.3 ± 0.8 4.60 ± 0.75
5 5 0.14 ± 0.02 7.6 ± 0.4 6.9 ± 0.2 3.8 ± 0.2 3.1 ± 0.3 1.3 ± 0.2 11.4 ± 0.2 2.6 ± 0.3 107.8 ± 2.3 146.4 ± 2.2 5.30 ± 0.84
Values represent mean ± SD, unless otherwise speciﬁed.
AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase; GLU: glucose; BUN: urea nitrogen; CREAT: creatinine; CHOL: choles-
terol; TRIG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; VLDL: very low-density lipoprotein cholesterol.
T BILI: total bilirubin; PHOS: inorganic phosphorus; T PROT: total protein; ALB: albumin; GLOB: globulin; A/G RATIO: albumin/globulin ratio; CA: calcium; MG: magnesium;
CL: chloride NA: sodium; K: potassium.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
* Statistically signiﬁcant at p 6 0.05 by Dunnett’s test.
Table 7
Clinical chemistry values for females.
EPGa
(g/kg bw/day)
N AST
(IU/L)
ALT
(IU/L)
GGT
(IU/L)
GLU
(mg/dL)
BUN
(mg/dL)
CREAT
(mg/dL)
CHOL
(mg/dL)
TRIG
(mg/dL)
HDL
(mg/dL)
LDL
(mg/dL)
VLDL
(mg/dL)
Week 6
0 5 64.4 ± 17.8 100.8 ± 22.6 56.3 ± 2.6 75.0 ± 22.1 17.2 ± 4.4 1.05 ± 0.23 114.2 ± 18.1 41.3 ± 6.0 61.4 ± 9.0 44.5 ± 14.2 8.3 ± 1.2
1.5 5 46.1 ± 10.0 112.3 ± 19.8 53.9 ± 6.0 65.4 ± 7.9 13.7 ± 4.8 0.80 ± 0.20 94.9 ± 22.9 25.8 ± 10.1 59.9 ± 9.3 29.8 ± 14.7 5.2 ± 2.0
3 5 37.7 ± 11.4* 103.8 ± 46.0 45.1 ± 8.4 66.0 ± 7.2 14.5 ± 3.0 0.92 ± 0.41 94.7 ± 17.2 44.1 ± 21.0 58.5 ± 12.2 27.4 ± 8.2 8.8 ± 4.2
5 5 43.1 ± 10.3* 92.0 ± 26.9 49.3 ± 8.8 67.6 ± 7.8 12.6 ± 2.5 0.79 ± 0.21 88.8 ± 19.8 36.5 ± 19.4 54.1 ± 18.3 27.5 ± 4.6 7.3 ± 3.9
Week 13
0 5 54.4 ± 14.6 99.5 ± 28.1 52.3 ± 5.8 76.2 ± 13.4 16.7 ± 3.8 1.04 ± 0.11 111.7 ± 13.9 44.1 ± 8.8 60.2 ± 9.1 42.7 ± 8.0 8.8 ± 1.8
1.5 5 67.2 ± 50.7 111.6 ± 22.8 59.4 ± 8.7 79.4 ± 19.0 14.2 ± 2.8 0.83 ± 0.15 97.9 ± 22.2 27.9 ± 14.0 62.2 ± 7.8 30.1 ± 14.4 5.6 ± 2.8
3 5 40.6 ± 4.9 96.1 ± 21.0 46.3 ± 8.7 65.7 ± 8.9 13.0 ± 1.5 0.94 ± 0.24 99.4 ± 21.6 35.0 ± 18.6 62.6 ± 10.3 29.8 ± 10.4 7.0 ± 3.7
5 5 47.0 ± 8.4 104.5 ± 22.2 51.3 ± 9.8 67.9 ± 5.3 11.8 ± 1.1* 0.89 ± 0.20 90.4 ± 19.3 31.6 ± 12.3 56.8 ± 13.3 27.3 ± 6.9 6.3 ± 2.5
T BILI
(mg/dL)
PHOS
(mg/dL)
T PRO
(g/dL)
ALB
(g/dL)
GLOB
(g/dL)
A/G RATIO CA
(mg/dL)
MG
(mg/dL)
CL
(mEq/L)
NA
(mEq/L)
K
(mEq/L)
Week 6
0 5 0.18 ± 0.04 7.3 ± 0.2 7.1 ± 0.5 3.7 ± 0.1 3.4 ± 0.4 1.1 ± 0.1 10.8 ± 0.1 2.4 ± 0.1 105.4 ± 2.2 138.8 ± 2.2 4.74 ± 0.33
1.5 5 0.14 ± 0.02 7.1 ± 0.8 6.5 ± 0.4* 3.4 ± 0.2 3.0 ± 0.3 1.1 ± 0.1 10.8 ± 0.6 2.2 ± 0.2 99.1 ± 7.0 137.6 ± 8.2 4.77 ± 0.58
3 5 0.14 ± 0.02 7.3 ± 1.1 6.7 ± 0.3 3.4 ± 0.3 3.3 ± 0.3 1.0 ± 0.2 10.8 ± 0.6 2.4 ± 0.4 98.1 ± 9.5 135.8 ± 9.5 4.82 ± 0.71
5 5 0.15 ± 0.04 7.1 ± 0.5 6.7 ± 0.3 3.4 ± 0.3 3.3 ± 0.4 1.0 ± 0.2 10.9 ± 0.5 2.4 ± 0.3 101.0 ± 3.6 138.9 ± 2.9 5.12 ± 0.74
Week 13
0 5 0.15 ± 0.02 7.1 ± 0.4 7.1 ± 0.3 3.7 ± 0.2 3.4 ± 0.1 1.1 ± 0.1 10.7 ± 0.5 2.3 ± 0.3 102.7 ± 4.9 140.2 ± 5.4 5.22 ± 0.99
1.5 5 0.17 ± 0.04 7.2 ± 0.5 6.5 ± 0.5 3.5 ± 0.2 3.0 ± 0.4 1.2 ± 0.2 10.6 ± 0.7 2.2 ± 0.2 102.3 ± 7.4 140.0 ± 8.9 5.15 ± 0.86
3 5 0.16 ± 0.02 7.5 ± 0.9 6.9 ± 0.4 3.7 ± 0.3 3.2 ± 0.4 1.2 ± 0.2 11.1 ± 0.7 2.5 ± 0.4 100.3 ± 6.3 140.2 ± 7.4 5.77 ± 0.86
5 5 0.19 ± 0.03 7.1 ± 0.2 6.8 ± 0.2 3.6 ± 0.2 3.2 ± 0.2 1.1 ± 0.2 10.6 ± 0.4 2.2 ± 0.1 102.0 ± 3.2 136.1 ± 2.8 5.24 ± 0.74
Values represent mean ± SD, unless otherwise speciﬁed.
AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase; GLU: glucose; BUN: urea nitrogen; CREAT: creatinine; CHOL: choles-
terol; TRIG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; VLDL: very low-density lipoprotein cholesterol.
T BILI: total bilirubin; PHOS: inorganic phosphorus; T PROT: total protein; ALB: albumin; GLOB: globulin; A/G RATIO: albumin/globulin ratio; CA: calcium; MG: magnesium;
CL: chloride; NA: sodium; K: potassium.
* Statistically signiﬁcant at p 6 0.05 by Dunnett’s test.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
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Table 8
Urinalysis values for males.
EPGa
(g/kg bw/day)
N VOL
(mL)
PHOS
(mg/dL)
CA
(mg/dL)
MG
(mg/dL)
CL
(mEq/L)
NA
(mEq/L)
K
(mEq/L)
Week 6
0 5 756 ± 451 9.2 ± 14.0 8.6 ± 4.3 20.2 ± 10.6 151.0 ± 26.4 71.5 ± 41.4 87.36 ± 31.71
1.5 5 595 ± 341 2.4 ± 1.4 13.2 ± 6.2 18.9 ± 11.4 119.7 ± 30.5 51.6 ± 25.5 71.40 ± 38.76
3 5 995 ± 256 2.2 ± 0.8 9.0 ± 4.1 17.8 ± 10.3 130.0 ± 67.0 54.1 ± 44.9 73.82 ± 32.19
5 5 722 ± 578 4.0 ± 4.8 6.7 ± 4.1 9.7 ± 8.6 120.7 ± 51.1 60.2 ± 51.1 74.08 ± 42.44
Week 12
0 5 1352 ± 902 15.4 ± 18.3 9.0 ± 3.0 22.8 ± 13.5 64. 4 ± 28.4 60.0 ± 24.8 61.01 ± 23.58
1.5 5 1235 ± 991 6.0 ± 6.2 8.8 ± 4.9 20.1 ± 7.4 71.7 ± 35.4 59.9 ± 38.4 83.82 ± 43.13
3 5 1726 ± 492 4.4 ± 4.3 7.0 ± 1.1 16.0 ± 7.8 54.5 ± 23.9 45.9 ± 18.2 51.15 ± 25.71
5 5 1053 ± 340 24.9 ± 53.7 9.3 ± 3.2 18.2 ± 20.3 62.3 ± 63.1 48.6 ± 48.3 61.93 ± 67.23
PHOS CHEM
(mg/kg/h)
CA CHEM
(mg/kg/h)
MG CHEM
(mg/kg/h)
CL CHEM
(mE/kg/h)
NA CHEM
(mE/kg/h)
K CHEM
(mE/kg/h)
Week 6
0 5 0.062 ± 0.039 0.109 ± 0.050 0.329 ± 0.279 0.254 ± 0.192 0.107 ± 0.089 0.128 ± 0.078
1.5 5 0.026 ± 0.015 0.137 ± 0.071 0.188 ± 0.056 0.145 ± 0.086 0.062 ± 0.050 0.078 ± 0.038
3 5 0.049 ± 0.020 0.213 ± 0.122 0.411 ± 0.229 0.275 ± 0.111 0.115 ± 0.076 0.162 ± 0.062
5 5 0.039 ± 0.025 0.083 ± 0.043 0.086 ± 0.037 0.163 ± 0.105 0.073 ± 0.053 0.093 ± 0.058
Week 12
0 5 0.183 ± 0.108 0.209 ± 0.138 0.409 ± 0.112 0.126 ± 0.053 0.123 ± 0.061 0.126 ± 0.063
1.5 5 0.105 ± 0.103 0.144 ± 0.077 0.355 ± 0.163 0.130 ± 0.072 0.107 ± 0.070 0.137 ± 0.064
3 5 0.140 ± 0.150 0.233 ± 0.080 0.500 ± 0.169 0.171 ± 0.054 0.146 ± 0.050 0.156 ± 0.034
5 5 0.223 ± 0.455 0.169 ± 0.073 0.253 ± 0.139 0.092 ± 0.053 0.073 ± 0.043 0.089 ± 0.053
Values represent mean ± SD, unless otherwise speciﬁed.
VOL: volume; PHOS: phosphorous; CA: calcium; MG: magnesium; CL: chloride; NA: sodium; K: potassium.
CHEM: chemistry; PHOS: phosphorous; CA: calcium; MG: magnesium; CL: chloride; NA: sodium; K: potassium.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
Table 9
Urinalysis values for females.
EPGa
(g/kg bw/day)
N VOL
(mL)
PHOS
(mg/dL)
CA
(mg/dL)
MG
(mg/dL)
CL
(mEq/L)
NA
(mEq/L)
K
(mEq/L)
Week 6
0 5 629 ± 284 9.6 ± 5.0 6.1 ± 2.7 13.5 ± 7.8 83.0 ± 15.1 61.6 ± 18.7 87.19 ± 16.67
1.5 5 361 ± 64 11.9 ± 9.6 12.5 ± 4.7 30.9 ± 17.4 139.6 ± 79.4 99.1 ± 66.9 124.00 ± 55.27
3 5 937 ± 390 12.5 ± 9.0 8.0 ± 5.6 15.3 ± 15.0 76.3 ± 38.2 54.1 ± 34.6 72.05 ± 35.68
5 5 774 ± 490 11.1 ± 7.6 6.9 ± 3.0 12.7 ± 11.0 60.7 ± 50.0 40.2 ± 43.7 59.04 ± 45.28
Week 13
0 5 1072 ± 560 1.8 ± 0.4 5.3 ± 1.5 9.1 ± 4.6 42.4 ± 12.1 33.6 ± 10.2 49.23 ± 16.79
1.5 5 1136 ± 486 2.2 ± 2.0 7.8 ± 1.3 8.0 ± 3.8 33.3 ± 14.7 29.3 ± 9.8 36.10 ± 16.08
3 5 1275 ± 855 7.8 ± 6.6* 5.7 ± 2.0 17.4 ± 5.8* 53.6 ± 18.5 39.3 ± 15.0 58.49 ± 20.58
5 5 1155 ± 453 2.5 ± 2.1 5.8 ± 2.8 9.7 ± 4.6 37.4 ± 20.2 31.1 ± 21.9 36.77 ± 17.89
PHOS CHEM
(mg/kg/h)
CA CHEM
(mg/kg/h)
MG CHEM
(mg/kg/h)
CL CHEM
(mE/kg/h)
NA CHEM
(mE/kg/h)
K CHEM
(mE/kg/h)
Week 6
0 5 0.129 ± 0.076 0.090 ± 0.061 0.223 ± 0.213 0.123 ± 0.079 0.093 ± 0.062 0.123 ± 0.065
1.5 5 0.136 ± 0.165 0.126 ± 0.082 0.291 ± 0.165 0.131 ± 0.076 0.093 ± 0.062 0.117 ± 0.058
3 5 0.309 ± 0.334 0.209 ± 0.230 0.345 ± 0.359 0.151 ± 0.065 0.107 ± 0.052 0.143 ± 0.060
5 5 0.208 ± 0.272 0.138 ± 0.142 0.191 ± 0.209 0.099 ± 0.094 0.066 ± 0.075 0.095 ± 0.084
Week 13
0 5 0.037 ± 0.028 0.108 ± 0.077 0.159 ± 0.085 0.077 ± 0.039 0.061 ± 0.033 0.085 ± 0.037
1.5 5 0.048 ± 0.050 0.199 ± 0.093 0.203 ± 0.136 0.085 ± 0.056 0.076 ± 0.045 0.089 ± 0.055
3 5 0.230 ± 0.283 0.146 ± 0.125 0.415 ± 0.306 0.125 ± 0.083 0.101 ± 0.075 0.129 ± 0.074
5 5 0.045 ± 0.032 0.133 ± 0.094 0.181 ± 0.032 0.068 ± 0.026 0.055 ± 0.028 0.069 ± 0.021
Values represent mean ± SD, unless otherwise speciﬁed.
VOL: volume; PHOS: phosphorous; CA: calcium; MG: magnesium; CL: chloride; NA: sodium; K: potassium.
CHEM: chemistry; PHOS: phosphorous; CA: calcium; MG: magnesium; CL: chloride; NA: sodium; K: potassium.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
* Statistically signiﬁcant at p 6 0.05 by Dunnett’s test.
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Liver and serum vitamin data are summarized in Table 10.
The mean liver vitamin A level of females receiving 5 g/kg bw/
day of EPG was signiﬁcantly (p 6 0.01) lower compared to control.In males, the mean liver vitamin A was also lower, but the differ-
ence was not statistically signiﬁcant, except when male and female
values were analyzed together (p 6 0.01).
The effect on liver vitamin E was the reverse: in females from
the 5 g/kg bw/day group, there was no apparent effect, whereas
Table 10
Liver and serum vitamin levels.
EPGa
(g/kg bw/day)
N Male Female
Liver
Vitamin Ab
(lg/g)
Liver
Vitamin Ec
(lg/g)
Serum
Vitamin D
(ng/mL)
Serum 25-OH-
Vitamin D
(ng/mL)
Liver
Vitamin Ab
(lg/g)
Liver
Vitamin Ec
(lg/g)
Serum
Vitamin D
(ng/mL)
Serum
25-OH-Vitamin D
(ng/mL)
0 5 60.4 ± 11.3 7.8 ± 0.8 1.9 ± 0.7 20.2 ± 1.4 73.4 ± 11.0 7.2 ± 1.1 2.8 ± 0.5 23.1 ± 1.8
1.5 5 ND ND 0.8 ± 0.2** 17.7 ± 2.0 ND ND 1.3 ± 1.0** 20.1 ± 4.1
3 5 ND ND 0.9 ± 0.4** 13.3 ± 2.7** ND ND 0.8 ± 0.3** 16.1 ± 3.1**
5 5 49.0 ± 12.8 6.8 ± 0.4* <0.5d 10.0 ± 1.2** 50.9 ± 8.5** 7.0 ± 0.7 <0.5d 10.9 ± 2.1**
ND: Not done.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
b Trans-retinol.
c a-Tocopherol.
d Below the limit of detection: 0.5 ng/mL.
* Statistically signiﬁcant at p 6 0.05 by Dunnett’s test.
** Statistically signiﬁcant at p 6 0.01 by Dunnett’s test.
Table 11
Fecal assay dataa.
EPGa
(g/kg bw/day)
N Male Female
Fatty acid
(g/100 g)
Cholesterol
(mg/100 g)
Calcium
(mg/100 g)
Fat
(ether extract)
(g/100 g)
Total
bile acids
(mM/100 g)
Fatty acid
(g/100 g)
Cholesterol
(mg/ 100 g)
Calcium
(mg/100 g)
Fat
(ether extract)
(g/100 g)
Total
bile acids
(mM/100 g)
Week 6
0 5 1.7 ± 0.3 87 ± 20 3704 ± 260 3.4 ± 0.8 0.588 ± 0.249 2.4 ± 0.2 75 ± 8 4452 ± 282 4.5 ± 0.9 0.457 ± 0.259
5 5 11.8 ± 2.3** 66 ± 15 2464 ± 288** 26.7 ± 2.3** <0.005b 9.5 ± 1.4** 52 ± 20* 2750 ± 293** 25.4 ± 1.6** 0.061 ± 0.125*
Week 12 or 13
0 5 1.7 ± 0.3 79 ± 09 4456 ± 389 3.2 ± 0.8 1.032 ± 0.143 2.0 ± 0.4 60 ± 10 3214 ± 468 4.4 ± 0.7 0.458 ± 0.311
5 5 10.4 ± 1.7** 44 ± 02** 2846 ± 153** 25.9 ± 4.4** 0.143 ± 0.287** 9.7 ± 1.8** 73 ± 11 2394 ± 278** 23.7 ± 2.5** 0.609 ± 0.327
Values represent mean ± SD, unless otherwise speciﬁed.
a Animals received feed containing 5%, 10%, and 17% EPG, mixed accordingly throughout the study to deliver 1.5, 3, and 5 g/kg bw/day of EPG, respectively.
b Below the limit of detection: 0.005 mM/100 g.
* Statistically signiﬁcant at p 6 0.05 by Dunnett’s test.
** Statistically signiﬁcant at p 6 0.01 by Dunnett’s test.
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male and female values were combined, there was no signiﬁcant
EPG-related effect on the vitamin E content of the liver (data not
shown).
Serum 25-OH-vitamin D levels were signiﬁcantly (p 6 0.01)
lower among animals receiving the two highest concentrations of
EPG (3 and 5 g/kg bw/day); the effect was not evident in animals
receiving 1.5 g/kg bw/day of EPG. Compared to control animals,
serum total vitamin D levels were signiﬁcantly (p 6 0.01) lower
across all groups receiving EPG. Values from all males and females
receiving 5 g/kg bw/day were below the assay limit of detection,
0.05 ng/mL; in females especially, the effect appeared to be related
to EPG concentration.
3.7. Tissue EPG
No EPG (triester) was found in the liver, kidneys, spleen, or adi-
pose tissue of animals from the control and 5 g/kg bw/day EPG
groups.
3.8. Fecal analysis
The results of fecal analyses are summarized in Table 11.
EPG was present, primarily as the triester, in the fecal samples
of all animals receiving 5 g/kg bw/day. Two control animals (1
male; 1 female) appeared to have traces of EPG diester and/or tri-
ester in the feces, but this was considered possibly artifactual by
the laboratory, since the fecal samples were no longer frozen when
received.Fecal total fat and fatty acid levels were signiﬁcantly (p 6 0.01)
greater among animals receiving EPG at 5 g/kg bw/day than con-
trol animals at all time points. A major increase was noted in the
percent of C18:0 and C22:0 saturated fatty acids in the feces of
EPG group males and females (data not shown).
Fecal calcium was signiﬁcantly (p 6 0.01) lower at all time
points among animals (males and females separately and com-
bined) receiving 5 g EPG/kg bw/day of EPG vs. the controls. This
might have been a volume-related effect, since no statistically sig-
niﬁcant differences were observed when the results on a mg/24-h
basis were compared (data not shown).
There was no clear effect of EPG treatment on the excretion of
cholesterol or bile acids. In males receiving EPG, fecal cholesterol
was lower, but reached statistically signiﬁcance only at the end
of the study. In females, fecal cholesterol was signiﬁcantly lower
only at Week 6.
In general, total bile acid was lower among animals receiving
EPG; in the case of males at Week 6, the levels were below the limit
of detection (0.005 mM/100 g). However, the relationship to EPG is
uncertain. By the end of the study, the difference for males was less
extreme (i.e., above the limit of detection) and there was no statis-
tically signiﬁcant difference for females.
3.9. Bowel transit time
Bowel transit times, as assessed by the time taken for radio-
opaque markers to travel the length of the gut over a 24-h period,
were comparable between the control group and the 5 g/kg bw/
day EPG group (data not shown).
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Gross ﬁndings in the lungs of subsets of animals from all groups,
including the control, were suggestive of pneumonia; the incidence
was greater among females. Histopathological examinations con-
ﬁrmed the ﬁnding of minimal to moderate chronic pneumonia
with inﬁltration of primarily lymphoid cells and macrophages.
The incidence among the groups was 5, 6, 6, and 3 animals each
from the 0, 1.5, 3, and 5 g/kg bw/day groups, respectively. Other
ﬁndings occurred across all groups or in individual animals, with
no evidence of a relationship to EPG (data not shown).
Evaluation of organ weight data showed no statistically signiﬁ-
cant differences, with the exception of the following: greater
(p 6 0.05) relative heart weight in females receiving 1.5 g/kg bw/
day; greater (p 6 0.05) relative thyroid weight in females receiving
1.5 g/kg bw/day and 5 g/kg bw/day; and greater (p 6 0.05) relative
spleen weight in females receiving 5 g/kg bw/day.4. Discussion
Dietary administration of EPG at concentrations of 1.5, 3, and
5 g/kg bw/day to micropigs for up to 13 weeks was associated with
some differences that reached statistical signiﬁcance. In general,
with the exception of the liver and serum vitamin levels, these
effects were seen sporadically and with no apparent connection
to EPG dose (not concentration-related) and/or no consistency
across time intervals. Effects on body weights might have been
the result of chronic pneumonia (otherwise asymptomatic) discov-
ered upon necropsy and histopathology, and/or stress from peri-
odic housing in metabolism cages.
Fecal excretion of total fat and fatty acids was signiﬁcantly
greater among animals receiving EPG. However, this effect was
not unexpected. Aside from the fat and fatty acids already present
in the feed (same as control), animals receiving EPG would have
consumed (and excreted) the fatty acids that are part of the EPG
molecule.
Serum 25-OH vitamin D levels were unaffected by EPG at 1.5 g/
kg bw/day; at 3 and 5 g/kg bw/day, EPG was associated with signif-
icantly lower levels. Serum total vitamin D levels were signiﬁcantly
lower across all EPG groups; in females, in a concentration-depen-
dent manner. There were also trends toward lower levels of liver
vitamins A and E among EPG-treated animals, but the effects were
less consistent.
The biological signiﬁcance of these ﬁndings is uncertain. EPG is
intended to replace fats and oils in food products, and similar sub-
stances have been shown to interfere with the absorption of lipid-
soluble nutrients. For example, pigs fed olestra for 4–26 weeks had
lower liver and serum concentrations of vitamins A and E, and
lower serum 25-OH vitamin D, in a dose-dependent manner
(reviewed by Tulley et al., 2005). Olestra has also been associated
with lower absorption of fat-soluble vitamins in humans
(Schlagheck et al., 1997). However, it seems unlikely that the
apparent effects of EPG of vitamin D in the present study would
have been due to interference with the metabolic conversion of
vitamin D in the liver to the biologically active metabolite (i.e.,
25-OH-vitamin D), since there was no indication that EPG was
absorbed. More importantly, the reductions in vitamin levels
observed in EPG-treated animals were not accompanied by any
signs of vitamin deﬁciency, as assessed by growth, clinical observa-
tions, clinical pathology, and anatomical pathology endpoints.
The decrease in serum vitamin D and 25-OH-vitamin D seen in
these pigs is signiﬁcantly greater than any observed in other spe-
cies tested (mouse, rat, dog, humans) and may be due to the rela-
tively greater mass of EPG (up to approximately 125 g/day)
administered in this study. The highest EPG concentration in thisstudy was 5 g/kg bw/day, while in other studies the greatest con-
centration was approximately 2 g/kg bw/day. Importantly, we
observed that the serum concentration of 25-OH-vitamin D did
not decline in proportion to the decline observed in the parent
vitamin and, in fact, a NOAEL for serum 25-OH-vitamin D was
established at the 1.5 g EPG/kg bw/day concentration. It seems rea-
sonable to conclude that the pigs efﬁciently converted available
vitamin D to maintain physiologically active concentrations of
the 25-hydroxy metabolite.
With respect to the role of dose mass, it seems useful to con-
sider that EPG, as a nondigestible lipid-like substance, might act
as a lipid ‘‘sink’’ or additional ‘‘compartment’’ for the distribution
of lipid-soluble substances, including fat-soluble vitamins present
in the gut lumen. However, EPG is not severely hydrophobic,
exhibiting a Kow value in the range of 3.2–3.4 similar to the tri-
glyceride fats it is intended to replace. Accordingly, lipid-soluble
substances partitioning into EPG are not strongly held and might
readily repartition back into the aqueous phase, establishing an
equilibrium state. While lipid-soluble nutrients are continuously
absorbed from the gut lumen by the usual physiological processes,
the solubility equilibrium would be expected to draw more of the
nutrient from the EPG compartment. As the unabsorbable EPG pro-
gresses down the gastrointestinal tract, beyond the area of active
nutrient absorption, it would still retain a certain amount of the
lipid-soluble nutrient. The amount retained would be in part pro-
portional to the mass of EPG present. This consideration may in
great part account for the observed signiﬁcant decrease in vitamin
D in the pigs, which received considerably greater amounts of EPG
than other animal species tested, and, importantly, amounts con-
siderably greater than the likely maximum daily intake by human
consumers.
The results of a subsequent 1-year study in pigs (data not shown)
conﬁrmed a no-observable-adverse-effect level (NOAEL) for total
25-OH-vitaminD between 1 and 2 g EPG/kg bw/day,with no indica-
tion of effects potentially attributable to vitamin D deﬁciency.
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